NCT02023593View on ClinicalTrials.gov

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2022

Conditions
Advanced Esophageal Carcinoma
Interventions
DRUG

FOLFIRI

Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yuhong Li

OTHER

NCT02023593 - FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma | Biotech Hunter | Biotech Hunter